RTOG Foundation
Open enrollment with an early-phase pipeline tilt
According to ClinicalTrials.gov-derived indexes, RTOG Foundation sits in the upper quartile of US sponsors by registered trial count (#2,085 of 15,742 sponsors by registered trial count).
RTOG Foundation: 6 sponsored US clinical trials, 1 recruiting.
RTOG Foundation sponsors 6 registered US clinical trials on ClinicalTrials.gov, 1 of them currently recruiting, and 1 completed. 1 of these trials are in Phase 3-4 (later-stage) and 5 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Head and Neck Squamous Cell Carcinoma (HNSCC), with 1 trials.
Upper-quartile sponsor footprint
RTOG Foundation sits in the upper quartile of the sponsor corpus (#2,085 of 15,742 sponsors by registered trial count) - denser than most sponsors, still short of the top-decile hubs.
Open and recent trials
6 total, page 1 of 1
Comparing the Radiopharmaceutical Drug, [177Lu]Lu-DOTATATE, to Standard of Care Treatment for Patients With Meningioma That Has Come Back After Prior Treatment
NCT06955169
A Study of Salvage Radiotherapy With or Without Enzalutamide in Recurrent Prostate Cancer Following Surgery
NCT03809000
SBRT +/- Pembrolizumab in Patients With Local-Regionally Recurrent or Second Primary Head and Neck Carcinoma
NCT03546582
Optune® Plus Bevacizumab in Bevacizumab-Refractory Recurrent Glioblastoma
NCT02743078
Cisplatin and Etoposide Plus Radiation Followed By Nivolumab/Placebo For Locally Advanced NSCLC
NCT02768558
Safety Testing of Adding Nivolumab to Chemotherapy in Patients With Intermediate and High-Risk Local-Regionally Advanced Head and Neck Cancer
NCT02764593
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 1 |
| Phase 2 | 4 |
| Phase 3 | 1 |
Therapeutic Areas
What is open in the RTOG Foundation pipeline
1 recruiting of 6 indexed (17% open); 1 completed (17%).
Phase mix: 1 late (III/IV) vs 5 early (I/II) (early-phase heavy).
Top condition: Head and Neck Squamous Cell Carcinoma (HNSCC) (1 trial), 2 others listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
RTOG Foundation: open-pipeline peers nationwide
Peers matched on 6 registered trials and 17% open enrollment, not the therapeutic-area sidebar.
RTOG Foundation sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 6 trials (± recruiting share)
- 23andMe · 6 trials · 0% recruiting
- Aardvark Therapeutics · 6 trials · 0% recruiting
- Abbisko Therapeutics Co · 6 trials · 67% recruiting
- AbGenomics B.V Taiwan Branch · 6 trials · 0% recruiting
Sponsors near 17% open enrollment (± trial volume)
- Adagene · 17% recruiting · 6 trials
- Agendia · 17% recruiting · 6 trials
- Akamis Bio · 17% recruiting · 6 trials
- Angiodynamics · 17% recruiting · 12 trials
Related
What to do with this RTOG Foundation page
6 registered trials is a research-attention snapshot, not an endorsement of RTOG Foundation or any single study.
- 1 of RTOG Foundation's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
- Head and Neck Squamous Cell Carcinoma (HNSCC) is the condition RTOG Foundation studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Head and Neck Squamous Cell Carcinoma (HNSCC) trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
RTOG Foundation pipeline card: 6 registered trials from official public datasets.Report a data error.